Edward Yu1, Miguel Ruiz-Canela2,3, Frank B Hu1,4,5, Clary B Clish6, Dolores Corella3,7, Jordi Salas-Salvadó3,8, Adela Hruby9, Montserrat Fitó3,10, Liming Liang11, Estefanía Toledo2,3, Emilio Ros3,12, Ramón Estruch3,13, Enrique Gómez-Gracia3,14, José Lapetra3,15, Fernando Arós3,16, Dora Romaguera3,17, Lluís Serra-Majem3,18, Marta Guasch-Ferré1, Dong D Wang1, Miguel A Martínez-González1,2,3. 1. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115. 2. Department of Preventive Medicine and Public Health, University of Navarra, and Instituto de Investigacion Sanitaria de Navarra (IdiSNA), University of Navarra, 31008 Pamplona, Spain. 3. CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, 28029 Madrid, Spain. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115. 5. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115. 6. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142. 7. Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain. 8. Human Nutrition Unit, Institut d'Investigació Sanitària Pere Virgili (IISPV), University Hospital of Sant Joan de Reus, Universitat Rovira i Virgili, 43201 Reus, Spain. 9. Jean Mayer United States Department of Agriculture (USDA) Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111. 10. Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, 08028 Barcelona, Spain. 11. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115. 12. Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, 08007 Barcelona, Spain. 13. Department of Internal Medicine, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, 08007 Barcelona, Spain. 14. Department of Preventive Medicine, University of Malaga, 29016 Malaga, Spain. 15. Department of Family Medicine, Research Unit, Primary Care Division of Sevilla, 41004 Sevilla, Spain. 16. Department of Cardiology, University Hospital Araba, 01009 Vitoria, Spain. 17. Instituto de Investigación Sanitaria de Palma (IdISPa), Hospital Universitari Son Espases, 07120 Palma de Mallorca, Spain. 18. Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, 35001 Las Palmas, Spain.
Abstract
Context: Arginine, its methylated metabolites, and other metabolites related to the urea cycle have been independently associated with cardiovascular risk, but the potential causal meaning of these associations (positive for some metabolites and negative for others) remains elusive due to a lack of studies measuring metabolite changes over time. Objective: To examine the association between baseline and 1-year concentrations of urea cycle metabolites and cardiovascular disease (CVD) in a case-cohort setting. Design: A case-cohort study was nested within the Prevención con Dieta Mediterránea trial. We used liquid chromatography-tandem mass spectrometry to assess metabolite levels at baseline and after 1-year follow-up. The primary CVD outcome was a composite of myocardial infarction, stroke and cardiovascular death. We used weighted Cox regression models (Barlow weights) to estimate multivariable-adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs). Setting: Multicenter randomized trial in Spain. Participants: Participants were 984 participants accruing 231 events over 4.7 years' median follow-up. Main Outcome Measure: Incident CVD. Results: Baseline arginine/asymmetric dimethylarginine ratio [HR per standard deviation (SD) = 0.80; 95% CI, 0.67 to 0.96] and global arginine availability [arginine / (ornithine + citrulline)] (HR per SD = 0.83; 95% CI, 0.69 to 1.00) were significantly associated with lower risk of CVD. We observed no significant association for 1-year changes in these ratios or any effect modification by the Mediterranean diet (MD) intervention. Conclusions: A higher baseline arginine/asymmetric dimethylarginine ratio was associated with lower CVD incidence in a high cardiovascular risk population. The intervention with the MD did not change 1-year levels of these metabolites.
Context:Arginine, its methylated metabolites, and other metabolites related to the urea cycle have been independently associated with cardiovascular risk, but the potential causal meaning of these associations (positive for some metabolites and negative for others) remains elusive due to a lack of studies measuring metabolite changes over time. Objective: To examine the association between baseline and 1-year concentrations of urea cycle metabolites and cardiovascular disease (CVD) in a case-cohort setting. Design: A case-cohort study was nested within the Prevención con Dieta Mediterránea trial. We used liquid chromatography-tandem mass spectrometry to assess metabolite levels at baseline and after 1-year follow-up. The primary CVD outcome was a composite of myocardial infarction, stroke and cardiovascular death. We used weighted Cox regression models (Barlow weights) to estimate multivariable-adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs). Setting: Multicenter randomized trial in Spain. Participants: Participants were 984 participants accruing 231 events over 4.7 years' median follow-up. Main Outcome Measure: Incident CVD. Results: Baseline arginine/asymmetric dimethylarginine ratio [HR per standard deviation (SD) = 0.80; 95% CI, 0.67 to 0.96] and global arginine availability [arginine / (ornithine + citrulline)] (HR per SD = 0.83; 95% CI, 0.69 to 1.00) were significantly associated with lower risk of CVD. We observed no significant association for 1-year changes in these ratios or any effect modification by the Mediterranean diet (MD) intervention. Conclusions: A higher baseline arginine/asymmetric dimethylarginine ratio was associated with lower CVD incidence in a high cardiovascular risk population. The intervention with the MD did not change 1-year levels of these metabolites.
Authors: Ramon Estruch; Miguel Angel Martínez-González; Dolores Corella; Jordi Salas-Salvadó; Valentina Ruiz-Gutiérrez; María Isabel Covas; Miguel Fiol; Enrique Gómez-Gracia; Mari Carmen López-Sabater; Ernest Vinyoles; Fernando Arós; Manuel Conde; Carlos Lahoz; José Lapetra; Guillermo Sáez; Emilio Ros Journal: Ann Intern Med Date: 2006-07-04 Impact factor: 25.391
Authors: Ramón Estruch; Emilio Ros; Jordi Salas-Salvadó; Maria-Isabel Covas; Dolores Corella; Fernando Arós; Enrique Gómez-Gracia; Valentina Ruiz-Gutiérrez; Miquel Fiol; José Lapetra; Rosa Maria Lamuela-Raventos; Lluís Serra-Majem; Xavier Pintó; Josep Basora; Miguel Angel Muñoz; José V Sorlí; José Alfredo Martínez; Miguel Angel Martínez-González Journal: N Engl J Med Date: 2013-02-25 Impact factor: 91.245
Authors: Maria Cristina D Thomazella; Marisa F S Góes; Cláudia R Andrade; Victor Debbas; Denise F Barbeiro; Renata L Correia; Sueli K N Marie; Arturo J Cardounel; Protásio L daLuz; Francisco R M Laurindo Journal: Am J Cardiol Date: 2011-09-03 Impact factor: 2.778
Authors: Rainer H Böger; Lisa M Sullivan; Edzard Schwedhelm; Thomas J Wang; Renke Maas; Emelia J Benjamin; Friedrich Schulze; Vanessa Xanthakis; Ralf A Benndorf; Ramachandran S Vasan Journal: Circulation Date: 2009-03-16 Impact factor: 29.690
Authors: Zeneng Wang; W H Wilson Tang; Leslie Cho; Danielle M Brennan; Stanley L Hazen Journal: Arterioscler Thromb Vasc Biol Date: 2009-06-18 Impact factor: 8.311
Authors: Peter Willeit; Daniel F Freitag; Jari A Laukkanen; Susmita Chowdhury; Reeta Gobin; Manuel Mayr; Emanuele Di Angelantonio; Rajiv Chowdhury Journal: J Am Heart Assoc Date: 2015-05-28 Impact factor: 5.501
Authors: Mark A McEvoy; John R Attia; Christopher Oldmeadow; Elizabeth Holliday; Wayne T Smith; Arduino A Mangoni; Roseanne Peel; Stephen J Hancock; Marjorie M Walker; Nicholas J Talley Journal: United European Gastroenterol J Date: 2021-08-25 Impact factor: 6.866
Authors: Cristina Razquin; Miguel Ruiz-Canela; Clary B Clish; Jun Li; Estefania Toledo; Courtney Dennis; Liming Liang; Albert Salas-Huetos; Kerry A Pierce; Marta Guasch-Ferré; Dolores Corella; Emilio Ros; Ramon Estruch; Enrique Gómez-Gracia; Montse Fitó; Jose Lapetra; Dora Romaguera; Angel Alonso-Gómez; Lluis Serra-Majem; Jordi Salas-Salvadó; Frank B Hu; Miguel A Martínez-González Journal: Cardiovasc Diabetol Date: 2019-11-13 Impact factor: 9.951
Authors: John P Hanrahan; Jelena P Seferovic; James D Wakefield; Phebe J Wilson; Jennifer G Chickering; Joon Jung; Kenneth E Carlson; Daniel P Zimmer; Andrew L Frelinger; Alan D Michelson; Linda Morrow; Michael Hall; Mark G Currie; G Todd Milne; Albert T Profy Journal: Diabetologia Date: 2019-12-19 Impact factor: 10.122
Authors: Manuela Ferrario; Roberta Pastorelli; Laura Brunelli; Shengchen Liu; Pedro Paulo Zanella do Amaral Campos; Daniela Casoni; Werner J Z'Graggen; Stephan M Jakob Journal: Sci Rep Date: 2021-09-16 Impact factor: 4.379